News Sharing
For sharing news, please enter the email address of you and the receiver, then press SEND button.*Mandatory Fields
Receiver*
Enter email addresses, separated by semicolon (;). E.g. a@a.com;b@b.com
Your email address*
 Content Sharing
<Research>Nomura: BEIGENE (06160.HK) Hikes No. of Preclinical Studies to 85 This Yr, Conducting 96 Clinical Trials
BEIGENE (06160.HK) held an R&D day in New York on Thursday (26th), where management emphasized the Company's R&D capabilities in terms of quality, speed and cost, Nomur...
Reset
Send
The window will close in 5 seconds
<Research>Nomura: BEIGENE (06160.HK) Hikes No. of Preclinical Studies to 85 This Yr, Conducting 96 Clinical Trials
Close
Recommend
5
Positive
7
Negative
0
 
SHORT SELL
 
STOCK INFO

BEIGENE (06160.HK)  -14.900 (-9.181%)    Short selling $160.75M; Ratio 7.867%   held an R&D day in New York on Thursday (26th), where management emphasized the Company's R&D capabilities in terms of quality, speed and cost, Nomura published a research report saying.

The Company has increased the number of preclinical studies from 20 in 2019 to 85 this year, while new molecules entering the clinical stage reached 10 in 2024.

Related NewsCMBI Recommends 3 3SBIO/ BEIGENE/ INNOVENT BIO/ GIANT BIOGENE; CN Pharmas to Face ST Pullback Pressure
The Company is currently conducting 96 clinical trials, with more than half involving solid tumors. Therefore, the broker rated BEIGENE at Buy, with a target price of $206.6.
(HK stocks quote is delayed for at least 15 mins.Short Selling Data as at 2025-06-27 16:25.)

AASTOCKS Financial News
Website: www.aastocks.com
Copyright(C) AASTOCKS.com Limited 2000. All rights reserved.
Disclaimer: AASTOCKS.com Ltd, HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the Information provided but do not guarantee its accuracy or reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.